Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (fGF23)-independent mechanism

Annals of Oncology

Volumn 22, Issue 4, 2011, Pages 988-990

  Bellini, E ^a   Pia, A ^a,b   Brizzi, M P ^a   Tampellini, M ^a   Torta, M ^a   Terzolo, M ^a,b   Dogliotti, L ^a   Berruti, A ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; CALCIUM; COLECALCIFEROL; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; SORAFENIB;

ADULT; CALCIUM BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; FEMALE; HUMAN; HYPOPHOSPHATEMIA; KIDNEY CANCER; LETTER; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN DEFICIENCY;

EID: 79953301961     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr010     Document Type: Letter

References (5)

1. Wilhelm SM, Adnane L, Newell P et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7(10): 3129-3140.
2. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell carcinoma. N Engl J Med 2007; 356: 125-134.
3. Berndt T, Kumar R. Phosphatonins and the regulation of phosphate homeostasis. Annu Rev Physiol 2007; 69: 341-359.
4. Razzasque MS. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 2009; 5: 611-619.
5. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.